Drug intelligence / Profile preview

ganoderma lucidum spore

Development stage: Phase 2
Administration: Oral

Overview

Ganoderma lucidum spore is the reproductive unit of the Reishi mushroom (Ganoderma lucidum), containing bioactive compounds including polysaccharides and triterpenes. These components are believed to have immunomodulatory, anti-inflammatory, antioxidant, and potential anticancer properties. Sporoderm-broken extracts (where the hard outer shell is cracked) are reported to have higher bioavailability and efficacy than unbroken spore extracts.

Other names: reishi mushroom sporelingzhi spore

Targets

KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)

Beyond the preview

Go deeper on ganoderma lucidum spore.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ganoderma lucidum spore.

Explore the full profile